L. C. Ajuria, M. Naigeon, R. Flippot, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C. Sautes-Fridman, M. Meylan, Y. Vano, B. Beuselinck, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, N. Chaput-Gras, L. Albiges
{"title":"184P 在 NIVOREN GETUG-AFU 26 研究中接受 nivolumab (nivo) 治疗的转移性透明细胞肾细胞癌(mRCC)患者(pts)中,基线循环 IL-8 升高与 IMmotion 髓系基因特征(GS)表达增加有关","authors":"L. C. Ajuria, M. Naigeon, R. Flippot, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C. Sautes-Fridman, M. Meylan, Y. Vano, B. Beuselinck, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, N. Chaput-Gras, L. Albiges","doi":"10.1016/j.iotech.2023.100643","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 55","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study\",\"authors\":\"L. C. Ajuria, M. Naigeon, R. Flippot, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C. Sautes-Fridman, M. Meylan, Y. Vano, B. Beuselinck, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, N. Chaput-Gras, L. Albiges\",\"doi\":\"10.1016/j.iotech.2023.100643\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":192507,\"journal\":{\"name\":\"Immuno-Oncology and Technology\",\"volume\":\" 55\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-Oncology and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.iotech.2023.100643\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study